MedTrace Logo

sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer

NCT02767921 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2021-11-24

No results posted yet for this study

Summary

This pilot clinical trial studies the side effects of recombinant EphB4-HSA fusion protein before surgery in treating patients with transitional cell carcinoma of the bladder, prostate cancer, or kidney cancer. Recombinant EphB4-HSA fusion protein may block an enzyme needed for tumor cells to multiply and may also prevent the growth of new blood vessels that bring nutrients to the tumor. Giving recombinant EphB4-HSA fusion protein before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Conditions

  • Infiltrating Bladder Urothelial Carcinoma
  • Recurrent Bladder Carcinoma
  • Stage I Prostate Cancer
  • Stage I Renal Cell Cancer
  • Stage II Bladder Urothelial Carcinoma
  • Stage II Renal Cell Cancer
  • Stage IIA Prostate Cancer
  • Stage IIB Prostate Cancer
  • Stage III Prostate Cancer
  • Stage III Renal Cell Cancer

Interventions

OTHER

Cytology Specimen Collection Procedure

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Radical Cystectomy

Undergo robotic-assisted radical cystectomy

BIOLOGICAL

Recombinant EphB4-HSA Fusion Protein

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo robotic-assisted radical or partial nephrectomy

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • David I Quinn, MD · University of Southern California

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-02
Primary Completion
2020-01-28
Completion
2021-11-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02767921 on ClinicalTrials.gov